ENXTPA:IPNPharmaceuticals
Assessing Ipsen (ENXTPA:IPN) Valuation After New Preclinical Oncology Data At AACR
Ipsen (ENXTPA:IPN) has come into focus after presenting fresh preclinical data at the AACR congress for two first in class oncology candidates, IPN01203 and IPN60300, targeting difficult solid tumor indications.
See our latest analysis for Ipsen.
The latest oncology data and recent conference activity come at a time when Ipsen’s share price has reached €157.7, with recent momentum reflected in a 90 day share price return of 32.97% and a 1 year total shareholder return of 48.68%. This...